Medication info

Balsar 40 mg Tablet (Valsartan)

Prescription medicationApproval withdrawn
Ingredient · strength
Valsartan›Strength being verified
Manufacturer / importer
Hanlim Pharmaceutical Co., Ltd.
Appearance
Yellow round oval film-coated tablet
Packaging
28 tablets (14 tablets/PTP packaging x 2), 30 tablets/bottle, 300 tablets/bottle
Approval status
Approval withdrawn

MFDS item code 201105414 · Notified 2011.08.18

This product's status changed to Approval withdrawn on 2023.07.18. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
Who uses it
Adults · Children
Adult dosage
(Tablets) * 40, 80, 160 mg 1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended that the medicine be taken at the same time every day (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended oral dose is 80 mg of valsartan once daily. The blood-pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg per day or a diuretic may be given concomitantly. If further blood-pressure reduction is needed, the dose may be increased to a maximum of 320 mg per day. 2) Elderly patients (75 years and older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dosage adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with intravascular volume depletion: In patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medicine once daily; do not exceed 80 mg per day. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administering a diuretic concomitantly, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg twice daily. Over the following several weeks, the dose may be increased, taking the patient's tolerability into account, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dosage adjustment is necessary when creatinine clearance is 10 mL/min or higher. However, because there is no experience with use in patients with creatinine clearance less than 10 mL/min or in patients on dialysis, do not administer this medicine. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If doses of 80 mg or more per day are administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Children's dosage
The safety and efficacy have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Hanlim Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction

  • Essential hypertension
  • heart failure
  • left ventricular dysfunction
  • left ventricular systolic dysfunction
View approved original text

This medication is used to reduce the risk of death in patients with essential hypertension, heart failure (particularly in patients who cannot use ACE inhibitors), and left ventricular dysfunction following myocardial infarction.

Dosage and Administration

Adult dosage

(Tablets) * 40, 80, 160 mg 1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended that the medicine be taken at the same time every day (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended oral dose is 80 mg of valsartan once daily. The blood-pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg per day or a diuretic may be given concomitantly. If further blood-pressure reduction is needed, the dose may be increased to a maximum of 320 mg per day. 2) Elderly patients (75 years and older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dosage adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with intravascular volume depletion: In patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medicine once daily; do not exceed 80 mg per day. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administering a diuretic concomitantly, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg twice daily. Over the following several weeks, the dose may be increased, taking the patient's tolerability into account, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dosage adjustment is necessary when creatinine clearance is 10 mL/min or higher. However, because there is no experience with use in patients with creatinine clearance less than 10 mL/min or in patients on dialysis, do not administer this medicine. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If doses of 80 mg or more per day are administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.

Children's dosage

The safety and efficacy have not been established in children and adolescents under 18 years of age.

Precautions

This drug can cause serious harm to the fetus or newborn if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. Women who are pregnant or may become pregnant, nursing mothers, patients with severe liver disease, severe kidney disease, and patients with a history of certain angioedema should not take this medication. Caution is especially advised for elderly patients, those with impaired kidney function, hyperkalemia, and heart failure patients, starting at a low dose and observing their condition. This drug lowers blood pressure, so caution is needed as dizziness or fainting may occur due to a rapid decrease in blood pressure when first taken. Patients on hemodialysis or those under strict sodium restriction should start with a low dose and increase it gradually while closely monitoring their condition. This drug can increase potassium levels when taken with other blood pressure medications, diuretics, or potassium-sparing drugs, so it is particularly important to manage patients with impaired kidney function carefully. Caution is also required when driving or operating machinery due to possible dizziness or drowsiness. Regular monitoring of kidney function, blood pressure, serum potassium, and other conditions should be performed while using this medication to check for any abnormalities. In case of overdose, hypotension, decreased consciousness, or shock may occur, so immediate emergency treatment is necessary, and hemodialysis is not effective. Safety and efficacy in children and adolescents have not been established, so use is not recommended. This medication should be kept out of reach of children, and transferring it to another container is not advisable for maintaining quality.

Side effects

headache

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air or moisture. It is also important to store it in a cool place below 30 degrees Celsius to maintain its effectiveness.

Appearance and packaging

Appearance

Yellow round oval film-coated tablet

Package unit

28 tablets (14 tablets/PTP packaging x 2), 30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.